Grant Awards
How have we all helped to advance LMS research? Just look at what the patient community has funded with Leiomyosarcoma Support & Direct Research Foundation (LMSDR.) But we can’t stop until we have a cure! Help us raise funds for next year’s researchers. Please donate to Leiomyosarcoma Support & Direct Research Foundation.
Each one of us can make a difference.
Together, we can make a change!
2021
$100.000 awarded to Dr. Joanna Przybyl (Stanford) for her 2-year project, “Metabolic Reprogramming in Leiomyosarcoma.” This study will identify drugs that will block sources of energy in cancer cells of three genetic subgroups of LMS.
2020
$100,000 awarded to Dr. van de Rijn (Stanford) for his continued work to distinguish uLMS from benign fibroids by a blood test. “Using Circulating Tumor DNA as a Measure of Tumor Load and Response to Therapy.”
2019
$47,000 awarded to Mathew Hemming MD PhD (Dana Farber) for his second year study of, “Exploring Leiomyosarcoma Functional Genomics to Identify Disease Specific Vulnerabilities.”
2018
$140,000 awarded to Dr. van de Rijn (Stanford) for his continued work to distinguish uLMS from benign fibroids by a blood test. “Using Circulating Tumor DNA as a Measure of Tumor Load and Response to Therapy.”
$74,000 awarded to Tatiana Omelchenko PhD (Sloan Kettering) for her study, “Identification of a Novel Treatment Strategy for Uterine Leiomyosarcoma in Genotype Defined Patient Population.” She will generate a genetically engineered mouse model based on genetic alterations found in uLMS patients and to model tumor growth inhibition. The $74,000 grant for this project was gifted by the Kelly Kimball family.
$10,000 sponsorship given to Kyle Floyd for his documentary, “Kicking the Hornets Nest.” This two-hour movie documents the history of uterine morcellation and the consequences for women with leiomyosarcoma.
2017
$40,000 awarded to Dr. Matt van de Rijn for his project titled: ROR2 and a Potential Target in Leiomyosarcoma.
$90,000 awarded to Dr. Matt van de Rijn (Stanford) for his continued work to distinguish uLMS from benign fibroids by a blood test. “Using Circulating Tumor DNA as a Measure of Tumor Load and Response to Therapy.”
2016
2015
2014
$110,000 awarded to Dr. Matt van de Rijn (Stanford) for his continued work to distinguish uLMS from benign fibroids by a blood test. “Using Circulating Tumor DNA as a Measure of Tumor Load and Response to Therapy.” In addition, he also plans to study:
- Clinically Relevant Molecular Subtypes in Leiomyosarcoma
- A Role for Versican in the Development of Leiomyosarcoma
- Progressive Loss of Myogenic Differentiation in Leiomyosarcoma Has Prognostic Value
2013
$50,000 awarded along with $100,000 from the Liddy Shriver Sarcoma Initiative to Dr. Matt van de Rijn (Stanford) for several LMS projects:
- The Study of Three Therapeutic Targets in Leiomyosarcoma
- Engineered SIRPa Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies.
- Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma
2011
$50,000 awarded jointly by LMSDR and the Liddy Shriver Sarcoma Initiative to Dr. Matt van de Rijn (Stanford) for several LMS projects:
- ROR2 is a Novel Prognostic Biomarker and a Potential Therapeutic Target in Leiomyosarcoma.
- The Effect of Mir-17-92 Dysregulation in Leiomyosarcoma-Genesis.
- Antibody Therapy Targeting the CD47 Protein is Effective in a Model of Aggressive Metastatic Leiomyosarcoma
- Flipping the Script on Macrophages in Leiomyosarcoma
- CFS1 Expression in Nongynological Leiomyosarcoma is Associated with Increased Tumor Angiogenesis
2010
2009
$25,000 awarded to Dr. Sandra Orsulic (Cedars Sinai) for her 2-year study, “A Role for BRCA1 in Uterine Leiomyosarcoma.”
2008
2007
2006
DONATE ONLINE

P.O. BOX
Support Group
Join our private Facebook support group.